Last edition
News about "semaglutide 2.4 mg"
Japan Approves Wegovy for MASH
Wegovy subcutaneous injection has been approved in Japan for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), becoming the first approved therapy for the disease in the country.
Semaglutide 2.4 Mg | 22/06/2026 | By News Bureau
Wegovy (Semaglutide 2.4 mg) reduced risk of heart attack, stroke, or death by 57 percent when compared to Tirzepatide, and 29 percent across all patients, showing heart-protective benefits unique to the Semaglutide molecule.
Semaglutide 2.4 Mg | 19/09/2025 | By Dineshwori | 259
Novo Nordisk's Wegovy Approved for Treatment of MASH in Adults with Liver Fibrosis
The US FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, according to Novo Nordisk.
Semaglutide 2.4 Mg | 16/08/2025 | By Dineshwori | 367
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy